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Abstract
Background: The epidemiology of malaria makes surveillance-based methods of estimating its disease burden problematic.
Cartographic approaches have provided alternative malaria burden estimates, but there remains widespread
misunderstanding about their derivation and fidelity. The aims of this study are to present a new cartographic technique
and its application for deriving global clinical burden estimates of Plasmodium falciparum malaria for 2007, and to compare
these estimates and their likely precision with those derived under existing surveillance-based approaches.
Methods and Findings: In seven of the 87 countries endemic for P. falciparum malaria, the health reporting infrastructure
was deemed sufficiently rigorous for case reports to be used verbatim. In the remaining countries, the mapped extent of
unstable and stable P. falciparum malaria transmission was first determined. Estimates of the plausible incidence range of
clinical cases were then calculated within the spatial limits of unstable transmission. A modelled relationship between
clinical incidence and prevalence was used, together with new maps of P. falciparum malaria endemicity, to estimate
incidence in areas of stable transmission, and geostatistical joint simulation was used to quantify uncertainty in these
estimates at national, regional, and global scales. Combining these estimates for all areas of transmission risk resulted in 451
million (95% credible interval 349–552 million) clinical cases of P. falciparum malaria in 2007. Almost all of this burden of
morbidity occurred in areas of stable transmission. More than half of all estimated P. falciparum clinical cases and associated
uncertainty occurred in India, Nigeria, the Democratic Republic of the Congo (DRC), and Myanmar (Burma), where 1.405
billion people are at risk. Recent surveillance-based methods of burden estimation were then reviewed and discrepancies in
national estimates explored. When these cartographically derived national estimates were ranked according to their relative
uncertainty and replaced by surveillance-based estimates in the least certain half, 98% of the global clinical burden
continued to be estimated by cartographic techniques.
Conclusions and Significance: Cartographic approaches to burden estimation provide a globally consistent measure of
malaria morbidity of known fidelity, and they represent the only plausible method in those malaria-endemic countries with
nonfunctional national surveillance. Unacceptable uncertainty in the clinical burden of malaria in only four countries
confounds our ability to evaluate needs and monitor progress toward international targets for malaria control at the global
scale. National prevalence surveys in each nation would reduce this uncertainty profoundly. Opportunities for further
reducing uncertainty in clinical burden estimates by hybridizing alternative burden estimation procedures are also
evaluated.
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Introduction
Estimating the disease burden posed by malaria is an
important public health challenge [1–9]. The clinical conse-
quences of Plasmodium falciparum infection have several features
that confound traditional approaches to disease burden and
disability measurement [10,11]. First, not all infections result in
progression to disease, notably in areas of stable transmission
[12], where populations have acquired clinical immunity [13].
The overall risk of clinical disease has a curvilinear and
uncertain association with the risk of infection as a combined
function of age at first infection and immunity [13–18]. Second,
the dominant symptom of fever, or other symptoms, does not
distinguish malaria from other locally prevalent infections
[19–23]. As a consequence, the routine reporting of ‘‘malaria’’
can overestimate disease rates by assuming that most fevers are
malaria [24,25] and that fevers associated with an infection are
causally linked to that infection [20,26]. Third, with few
exceptions across malaria-endemic countries, fevers or other
malaria-like syndromes are often self-medicated and may
resolve regardless of cause before reaching formal health
systems [27]. Fourth, inaccurate diagnoses [21,25,28] might
be used to report disease rates, and these errors may be
compounded through inadequate and incomplete national
reporting systems [29–38].
To circumvent some of the clinical, treatment, and reporting
problems inherent in malaria burden estimation, we previously
computed the global incidence of P. falciparum clinical disease [5]
for 2002, using assemblies of epidemiological data and a modified
categorical map of historical malaria endemicity [39]. The
publication of (i) the revised global spatial limits of P. falciparum
transmission [40], (ii) a contemporary geostatistical description of
P. falciparum malaria endemicity within these limits [41], and (iii)
updates of the modelled relationship between clinical incidence
and prevalence [42] have resulted in a substantially improved
evidence base from which to revisit estimates of the clinical burden
of P. falciparum, defined as the primary acute clinical event resulting
from malaria infection at all ages. Most significantly, a
geostatistical space–time joint simulation framework [43] is
combined with these improved cartographic and epidemiological
data sources to quantify uncertainty in the mapped outputs and to
propagate it appropriately into the derived burden estimates.
Using these joint simulation procedures we have built upon
previous approaches to produce the first continuous map of global
clinical P. falciparum incidence, and we use this to estimate the
global clinical burden of P. falciparum malaria in 2007. These
estimates are then compared with those available from surveil-
lance, and the opportunity for the further hybridization of these
techniques is discussed.
Methods
Analysis Outline
A schematic overview of the analysis procedures is provided in
Figure 1. In brief, of the 87 countries classified as endemic for P.
falciparum malaria [40], seven had sufficiently reliable health
information systems for case report data to be used directly to
enumerate clinical burden for 2007. We divided the population
at risk (PAR) in the remaining 80 countries into regions of
unstable and stable risk of transmission [40] (Figure 2). In
unstable regions, a uniform clinical incidence rate was adopted
of 0.1 case per 1,000 per annum (PA). This rate was multiplied
by a population surface [44] for 2007 (Figure 3) and aggregated
to obtain country and regional case estimates for these unstable
areas. Upper and lower bounds were defined using uniform rates
of zero and one case, respectively, per 1,000 PA. In stable
regions, we used a previously defined Bayesian geostatistical
model that took an assembly of space–time distributed P.
falciparum parasite rate (PfPR) surveys and generated realisations
of continuous age-standardized prevalence within the limits of
stable transmission [41]. We then used a Bayesian nonparamet-
ric model [42] of a collection of all-age active case detection
studies, to describe the uncertain relationship between the
clinical incidence rate and the underlying age-standardized
parasite prevalence. These two models were integrated in a
geostatistical space–time joint simulation framework to generate
joint realisations of clinical attack rate for every pixel as a
function of the predicted underlying prevalence [43] (Protocol
S1). These attack rates were then multiplied by the correspond-
ing pixel population totals to yield joint realisations of a clinical
burden surface (Figures 4 and 5). This joint simulation
framework supported the aggregation of per-pixel burden
estimates into defined spatial units, whilst preserving a space–
time uncertainty structure, allowing country and regional
estimates of burden to be made with appropriate credible
intervals (Table 1, Protocol S2). Each of these analytical
components are now discussed in more detail.
Defining Populations and Global Regions
The Global Rural Urban Mapping Project (GRUMP) alpha
version [44] provides gridded population counts and population
density estimates for the years 1990, 1995, and 2000, adjusted to
the United Nations’ national population estimates. Population
counts for the year 2000 were projected to 2007 by applying
national, medium variant, intercensal growth rates [45] by country
using methods previously described [46] (Figure 3).
We have modified the World Health Organization (WHO)
regional country groupings, recognizing that these geopolitical
boundaries do not conform to the biogeographical determinants of
malaria risk and thus disease burden [41,47,48]. For the purposes
of disease risk estimation we have used three malaria regional
groupings: Africa+ (including Yemen and Saudi Arabia, which
share the same dominant Anopheles vectors as mainland Africa
[49]), the Americas, and the combined regions of Near East, Asia,
and the Pacific that we refer to as Central and South East (CSE)
Asia (Figure 2). To facilitate comparison with other estimates,
however, we have also shown the results aggregated by the
regional groupings of the WHO (Protocol S2).
Defining the Limits of Stable and Unstable P. falciparum
Transmission
To define the global spatial limits of P. falciparum transmission,
we previously assembled confirmed P. falciparum clinical case
data for 41 P. falciparum malaria-endemic countries (PfMECs)
outside of Africa [40]. National case reported data were
expressed as P. falciparum annual parasite incidence (PfAPI)
derived from various combinations of active case detection
(fever surveys in communities where every person presenting
with a fever is tested for parasite infection) and passive case
detection (reports from febrile patients attending the local health
services) and usually expressed together as the number infected
per 1,000 PA [50–52]. These data were provided by malaria
coordinating officers in the WHO regional offices of the Eastern
Mediterranean (EMRO), Europe (EURO), South East Asia
(SEARO), and the Western Pacific (WPRO) at the highest
available administrative level unit between 2002 and 2007.
Among the countries in the American Regional Office (AMRO),
PfAPI data from national surveillance systems in Brazil,
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Figure 1. Schematic diagram showing the procedure for burden estimation. Blue boxes describe input data, orange boxes models and
experimental procedures, dashed green rods intermediate output, and solid green rods the final output. The seven countries with reliable national
reporting were Belize, Iran, Kyrgyzstan, Panama, Saudi Arabia, South Africa, and Tajikistan. The areas of unstable and stable transmission are defined
as having less or more than one case per 10,000 PA, respectively [40,41].
doi:10.1371/journal.pmed.1000290.g001
Figure 2. Global limits and endemicity of P. falciparum in 2007. The land area was defined as no risk (light grey), unstable risk (medium grey
areas, where PfAPI ,0.1% PA), and stable risk (where PfAPI .0.1% PA) [40] with endemicity (PfPR in the 2- up to 10-year age group, PfPR2–10)
displayed as a continuum of yellow to red between 0% and 100%. The dashed lines separate the Americas, Africa+, and the CSE Asia region,
respectively, from left to right. The seven countries with thick blue borders have very low P. falciparum burden and reliable national health
information systems.
doi:10.1371/journal.pmed.1000290.g002
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Colombia, Peru, and Honduras were obtained directly from
personal communication with national malaria specialists.
The PfAPI data were mapped to first, second, or third
administrative level units and used to classify areas as no risk (zero
cases) and either unstable or stable risk if the number of confirmed
cases was lower or higher than 0.1 case per 1,000 PA, respectively
[40]. The unstable/stable classification was based on a review of
the statistical, logistical, and programmatic reasons underpinning
the PfAPI levels used to define phases and action points
during the Global Malaria Eradication Program [12,53–55]. In
addition, no transmission was assumed where medical intelli-
gence from international travel advisories or national malaria
control programmes stated no malaria risk or where the
temperature was too low for sporogony to complete within
the average lifespan of the local dominant vector species [49].
Measures of aridity were used to define areas in which
transmission is biologically plausible in isolated manmade
breeding sites, but overall transmission in surrounding areas is
limited by its effects on anopheline survival, and the clinical
incidence is likely to be less than 0.1 case per 1,000 PA. The
spatial extents of stable and unstable risk defined using these
inputs are shown (Figure 2).
Defining P. falciparum Clinical Incidence in Areas of
Reliable Case Detection
Paradoxically, where the incidence of clinical malaria events are
rare, their rapid detection and notification becomes increasingly
important as part of national malaria control strategies, demanding
more sophisticated surveillance [51,55–57]. This is particularly true
for countries aiming to attain or maintain WHO accredited
elimination status [58–60]. Of the 87 PfMECs, we have identified
seven countries that are relatively wealthy and have specified a goal
Figure 4. Global clinical burden of P. falciparum in 2007. Bayesian geostatistical estimates (posterior means) of the number of all-age clinical
cases per 565 km pixel displayed on a logarithmic colour scale between 0 and 10,000 cases, within the stable limits of P. falciparum transmission.
Dark and light grey areas are as described in Figure 2.
doi:10.1371/journal.pmed.1000290.g004
Figure 3. Global human population density in 2007. Human population density [44] in persons per km2 is displayed on a logarithmic colour
scale within the limits of P. falciparum transmission. No malaria risk is shown in light grey.
doi:10.1371/journal.pmed.1000290.g003
Global Malaria Burden
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of P. falciparum elimination where case-detection systems are an
integral part of the control strategies [58–60]: Panama, Belize,
Tajikistan, Kyrgyzstan, Iran, Saudi Arabia, and South Africa
(Figure 2). For these seven countries, we have used the national
reports for 2007 of all notified, locally acquired infections submitted
to regional WHO offices (see Acknowledgments) as the definitive
estimate of case burden. These countries are characterised by
having a small number of annual cases, with a large proportion of
the population living in areas of no risk or unstable transmission and
are therefore likely to represent a very small proportion of the global
P. falciparum malaria burden [40].
Defining Malaria Incidence in Areas of Unstable P.
falciparum Malaria Transmission
We estimate that almost one billion people were living in areas
where P. falciparum transmission was unstable in 2007 [40]
(Figure 2). Defining annualized disease risk in these areas from
empirical data is difficult, as epidemiological investigations for
research or survey purposes are rare. Nevertheless, in computing
disease burdens it is important to impute some measure of
completeness of formal malaria reporting within these marginal,
unstable transmission areas. A number of malaria treatment-
seeking behaviour studies and qualitative examinations of routine
malaria reporting frequency suggest large inadequacies in a range
of national reporting systems from a variety of causes that can act
multiplicatively: Cambodia (actual number of cases 2.76 greater
than reported) [35], India (9–506) [28,61–65], Mozambique
(2.76) [32], Pakistan (5.96) [30], Peru (4.36) [34], Solomon
Islands (4.76) [38], Sri Lanka (1.96) [29], and Syria (4.56)
[31].
There are remarkably few specific investigations of the
completeness of malaria case notification systems in different
settings. Only four reports provide an estimate of the numbers of
cases likely to be missed by routine health system surveillance
compared to more aggressive, active case detection methods in the
same communities over the same time period. In the Yanomami
area of Brazil, approximately 1.25 more events were detected by
active detection than were reported to the routine health system
[57]. Across different years at different sites the ratio of active to
routine, passive detection varied from 4.5 to 42.1 in Vietnam [66],
with similar under-reporting rates documented in Cambodia [67].
A 5-fold difference in survey-to-passive rates of case detection has
been reported in Yunnan Province in China [68]. It is not possible
to provide an evidence-based under-reporting correction factor that
Figure 5. Uncertainty in the global clinical burden of P. falciparum in 2007. Bayesian geostatistical model-based prediction uncertainty
(posterior standard deviations) on a logarithmic colour scale between 0 and 20,000 cases, within the stable limits of P. falciparum transmission. No
model-based uncertainty metrics were produced for areas of unstable transmission. Dark and light grey areas are as described in Figure 2.
doi:10.1371/journal.pmed.1000290.g005
Table 1. Numbers of Plasmodium falciparum clinical attacks by region globally in 2007.
Category Americas (16 countries) Africa+ (47 countries) CSE Asia (19 countries) Total
Reliable reporting (casesa) 32 (Panama, Belize) 2,717b (Saudi Arabia, South
Africa)
618 (Kyrgyzstan, Tajikistan, Iran) 3,367
Unstable riskc (casesa) 5,455 (0–54,550) 1,892 (0–18,920) 98,049 (0–980,490) 105,395 (0–1,053,950)
Stable riskc (millions of casesa) 3.04 (1.17–6.70) 270.88 (241.13–300.56) 176.90 (89.21–269.58) 450.83 (348.76–552.22)
Total (millions of casesa) 3.05 (1.17–6.76) 270.89 (241.13–300.58) 177.00 (89.21–270.56) 450.93 (348.76–553.27)
The regional groupings are illustrated in Figure 1.
aCase numbers from countries with reliable reporting and areas of unstable risk are presented directly whilst those from areas of stable risk are presented in millions of
cases, rounded to the nearest 10,000, reflecting the larger numbers and lower precision associated with these model-based estimates.
bPresumed to be all P. falciparum, although autochthonous case reports did not specify.
cExcluding countries with reliable case data.
doi:10.1371/journal.pmed.1000290.t001
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is specific for every national malaria information system. We have
therefore elected to use a single worst-case rate of 10-fold under-
reporting across all countries. We hence assume for all unstable
areas a uniform incidence of 0.1 case per 1,000 PA, with a lower
confidence bound of zero and an upper confidence bound assuming
a 10-fold under-reporting rate; equating to one case per 1,000 PA.
Defining Malaria Incidence in Stable Endemic Areas
We estimated that in 2007, approximately 1.4 billion people
lived in areas of stable P. falciparum transmission [40] (Figure 2). In
these areas, we considered that case-reporting through routine
health information systems was too unreliable for the calculation of
incidence due to inadequate reporting coverage (see above),
widespread self-medication [27], and poor diagnosis [21,25].
Instead, we developed a model-based cartographic method for
deriving estimates in the areas of stable transmission in which
clinical incidence was modelled as a function of the underlying
endemicity (parasite prevalence). This procedure required: (i) a
spatially continuous model for endemicity; (ii) a further model to
predict incidence as a function of endemicity; (iii) reliable data on
2007 population distribution; and (iv) a technique for combining
these components so that the uncertainty inherent in the
component models was propagated into the resulting burden
estimates. These components are now outlined in turn, with
additional statistical details provided in Protocol S1.
To estimate stable transmission intensity, a Bayesian space-time
geostatistical modelling framework was developed to interpolate
empirical estimates of age-corrected parasite prevalence derived
from 7,953 community surveys undertaken between 1985 and
2008 across 83 malaria-endemic countries. This model has been
described in detail elsewhere [41] and its output allows for a
continuous, urban-adjusted, contemporary estimate of parasite
prevalence in children aged from 2 up to 10 years (PfPR2–10) at a
pixel spatial resolution of 565 km for the year 2007 (Figure 2).
To estimate clinical incidence, formal literature searches were
conducted for P. falciparum malaria incidence surveys undertaken
prospectively through active case detection at least every 14 days
[42]. The incidence surveys were time–space matched with
estimates of parasite prevalence derived from the geostatistical
model described above [41]. Potential relationships between all-
age clinical incidence and age-standardized parasite prevalence
were then specified in a nonparametric Gaussian process model
with minimal, biologically informed, prior constraints. A temporal
volatility model was incorporated to describe the variance in the
observed data and Bayesian inference was used to choose between
the candidate models [42]. Separate relationships were preferred
for each of the three regions defined globally (Figure 2) to
accommodate regional-specific differences in the dominant vector
species [47,49,69], the impact of drug resistance on recrudescent
clinical attacks [70], the possible modification of P. falciparum
clinical outcomes in areas of P. vivax co-infection [71,72], and the
genetic contribution to disease risk of inherited haemoglobin
disorders [73]. Due to the sparse data in the Americas, however,
this region was combined with CSE Asia. In the Africa+ region
and the combined Americas and CSE Asia region, clinical
incidence increased slowly and smoothly as a function of infection
prevalence (Figures 6, 7, 8, and 9). In the Africa+ region, when
infection prevalence exceeded 40%, clinical incidence reached a
maximum of 500 cases per 1,000 PA (Figure 6). In the combined
Americas and CSE Asia regions this maximum was reached at 250
cases per 1,000 PA (Figure 7).
Both the geostatistical endemicity and the endemicity–
incidence models were specified in a fully Bayesian framework.
The output of the former was a large set of realisations
(n = 250,000): possible maps that, together, represented the
modelled uncertainty in endemicity at each location. Similarly,
the output of the endemicity–incidence model was a large set
(n = 250,000) of possible forms of the endemicity-incidence curve
that encompassed the modelled uncertainty in this relationship
(Figures 6, 7, 8, and 9). To combine the uncertainty from both
models, each realisation of the uncertainty map was used as input
into a realisation of the endemicity–incidence model to obtain a
realisation of a 565 km resolution incidence map. This was
downscaled to 161 km resolution and multiplied with the 2007
population surface to obtain, for every grid square, a realisation
of the number of clinical cases in 2007. By repeating this
Figure 6. The posterior distribution of the prevalence-inci-
dence relationship (h p,Tð Þ, see Methods) in the Africa+ region.
The relationship is plotted between malaria endemicity (PfPR in the 2-
up to 10-year age group, PfPR2–10) and all-age incidence (clinical cases
per thousand of the population PA) [42]. Please see reference [42] for a
full description of the data, methods, and techniques used to define this
relationship. The light grey, medium grey and dark grey regions define
the 95%, 50%, and 25% credible intervals, respectively. The solid black
line is the median and the data are shown as red dots.
doi:10.1371/journal.pmed.1000290.g006
Figure 7. The posterior distribution of the prevalence-inci-
dence relationship (h p,Tð Þ, see Methods) in the combined CSE
Asia region and the Americas. The techniques and colours used are
identical to Figure 6.
doi:10.1371/journal.pmed.1000290.g007
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procedure for every model realisation, a set of 250,000 burden
values was generated for every grid square, approximating a
complete posterior distribution for the estimates. Because each
realisation of the endemicity map was jointly simulated, rather
than calculated on a pixel-by-pixel basis, each realisation of
burden could be aggregated spatially or temporally, whilst
maintaining the correct variance structure. This allowed burden
realisations at each pixel to be combined spatially to generate
estimates of national and regional burdens with appropriate
credible intervals. Joint simulation at this scale is enormously
computationally intensive and a bespoke algorithm was devel-
oped to implement this stage of the analysis. The algorithm is
presented elsewhere [43] and the statistical details are summa-
rised in Protocol S1.
Results
The combined clinical burden of the seven nations with
comprehensive reporting was 3,367 cases in 2007 (Table 1,
Protocol S2). Multiplying the population surface (Figure 3) by the
assumed incidence rate in unstable areas (see Methods) produced
an estimate of 105,395 clinical cases of P. falciparum malaria in
areas of unstable transmission (Table 1, Protocol S2), with a
plausible range between zero and 1,053,950. The modelling
procedures in the stable areas generated an estimate of 451 million
cases (lower 95% credible interval 349 million and upper 95%
credible interval 552 million) of P. falciparum malaria in areas of
stable transmission in 2007, of which 271 (241–301) million were
estimated to have occurred in the Africa+ region, 177 (89–270)
million in the CSE Asia region and 3 (1–7) million in the Americas
(Table 1).
Combining our estimates from the seven countries with
comprehensive case reporting with those from areas of unstable
and stable transmission in the remaining 80 PfMECs, we estimate
that in 2007 there were 451 (349–553) million clinical cases of P.
falciparum malaria. A continuous map of these incidence predic-
tions is provided (Figure 4), with an additional map of the pixel-
specific uncertainty (Figure 5). In addition to the regional
summaries presented (Table 1), estimates of clinical burden are
summarized for each country and for each of the WHO global
regions (Figure 10 and Protocol S2). It is notable that more than
half (51%) of the world’s estimated P. falciparum clinical cases
derive from just four countries: India, Nigeria, DRC, and
Myanmar (Burma) (Figure 4 and Protocol S2) and that, in
addition, these nations contribute 48% of the uncertainty (Figure 5)
in the global incidence estimates.
Regional summary estimates of P. falciparum malaria cases in
unstable and stable transmission areas are summarized in Table 1
and are also shown for the WHO regions in Figure 10. It is clear
that African populations suffered the largest proportion (60%) of
the 451 million clinical cases of P. falciparum estimated globally in
2007 (Figure 10, Table 1 and Protocol S2). The highest-burden
countries in Africa are Nigeria and DRC, both countries with
extensive regions of high endemicity (Figure 2) and large
populations (Figure 3). These two countries account for 23% of
the world’s P. falciparum disease burden (Protocol S2). Less than 1%
of the global P. falciparum burden occurred in the Americas, where
transmission intensity is almost universally low or unstable
(Figure 2). We estimate that the remaining 39% of global burden
in 2007 occurred in the CSE Asia region (Table 1). In this region,
the immense population living at risk of P. falciparum malaria
means that, despite a low prevalence [41] (Figure 2) and the lower
endemicity–incidence relationship [42] (Figure 7), cases in CSE
Asia add substantially to the global disease burden (Table 1). At a
country level, India and Myanmar contribute 22.6% and 5.8%,
respectively, of the total number of clinical cases due to P.
falciparum worldwide (Protocol S2).
Discussion
We have used a combination of methods, including a joint
simulation of incidence in areas of stable transmission, to estimate
451 (349–552) million clinical cases of P. falciparum malaria in
2007: 3 (1–7) million in the Americas, 271 (241–301) in the
Africa+ region, and 177 (89–270) in the CSE Asia region.
Figure 8. The predictive distribution of the incidence that
would actually be observed by weekly surveillance over a two-
year period in the Africa+ region. Please see reference [42] for a full
description of the data, methods, and techniques used to define this
relationship. The light grey, medium grey, and dark grey regions define
the 95%, 50%, and 25% credible intervals, respectively. The solid black
line is the median and the data are shown as red dots. Note that the
data points were collected using different surveillance intervals over
different time periods, and therefore should not be expected to follow
the distribution predicted by the model exactly. The observed
incidences are included in the figure as a visual aid only.
doi:10.1371/journal.pmed.1000290.g008
Figure 9. The predictive distribution of the incidence that
would actually be observed by weekly surveillance over a two-
year period in the combined CSE Asia region and the Americas.
The techniques and colours used are identical to Figure 8.
doi:10.1371/journal.pmed.1000290.g009
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Morbidity in Areas of Unstable Transmission
We have accepted as accurate the surveillance reports of seven
relatively high income and low burden PfMECs, all nations with
credible plans for malaria elimination [59,60,74–76]. We have
further attempted to describe clinical disease incidence in areas of
the world that we classify as unstable risk [40], which were home
to almost a billion people in 2007. We know relatively little about
the epidemiology of P. falciparum in the 40% of the global PAR of
P. falciparum malaria living in unstable transmission areas. These
areas are notoriously difficult to define in terms of potential
disease outcomes; they may go several years without a single
autochthonous case, transmission is extremely focal and,
importantly, investigation of the clinical epidemiology is prohib-
itively expensive because of the rarity of the disease [77]. We
have, therefore, defaulted to national reporting systems as an
entry point to the definition of risk and have used surveys of
under-reporting rates to define plausible ranges of the disease
burden in these marginal transmission zones. We estimate that
there were 105,395 (0–1,053,950) cases of P. falciparum in unstable
transmission areas in 2007. Despite being relatively crudely
defined, these sums represent only 0.02% of the global clinical P.
falciparum burden. Therefore, while these cases are of significant
concern to those nations with large populations at unstable risk
and to those considering elimination [59,60,74–76], they make a
very small contribution to the estimation of the global P.
falciparum burden.
Morbidity in Stable Areas
We have improved upon a P. falciparum disease burden
estimation rubric that has been used several times previously for
Africa [1,3,4,6,7] and once before globally [5]. This method
requires an understanding of the basic clinical epidemiology of P.
falciparum malaria, its relationship to transmission intensity and the
use of empirical, longitudinal observations in populations exposed
to different conditions of transmission. However, these empirical
studies of clinical incidence are not without their own caveats [42].
Longitudinal surveillance over a complete annual malaria
transmission cycle within the same cohort is likely to underesti-
mate the ‘‘natural’’ risk of disease given the ethical need to treat
effectively all detected infections or clinical events. These studies
are also conducted throughout a range of region-specific co-species
infection [78], HIV/AIDS prevalence [79], and drug resistance
[80] conditions. The number of studies meeting our inclusion
criteria remains low, so these covariate determinants of clinical risk
cannot be adequately modelled or controlled for in this series [42].
We have considered all infections that are associated with a
reported or measured febrile event as clinical malaria. This seems
appropriate under conditions of low transmission intensity, but as
transmission intensity increases, the proportion of fevers that can
be causally linked to malaria infection declines [26,81]. Conse-
quently, our estimates of clinical attack rates at the highest levels of
transmission are likely to be overestimates of true P. falciparum
clinical incidence. Locally derived age- and transmission-depen-
dent aetiological fraction estimates were not available for the
majority of studies in order to allow the application of meaningful
corrections. Conversely, the use of fever and any level of
peripheral infection to define a malaria case corresponds closely
to the criteria recommended for case treatment across the world
[82,83] and thus has congruence with disease burdens that should
be managed with appropriate medicines. Finally, we have not
considered the impact of scaled or partial coverage of interventions
aimed at preventing infection, because we feel this is reflected in
the parasite prevalence surface [41]. The one exception is the use
of failing monotherapy because recrudescent cases will not be
reflected in our endemicity–incidence relationship based on active
case detection with effective treatment and thus, where this poses a
significant threat, our estimates will be even greater underesti-
mates. Despite the caveats, we believe that this approach to P.
falciparum disease burden estimation provides an alternative and, in
nations with inadequate surveillance, the only existing approach to
estimating the true global risk of malaria.
Robust Estimates of Uncertainty
We have used joint simulations from an established Bayesian
geostatistical model for P. falciparum parasite prevalence in the 2-
up to 10-year age group (PfPR2–10) (Figure 2), integrated with a
second Bayesian model for the endemicity-incidence relationship
(Figures 6 and 7), to generate spatially distributed estimates of the
clinical burden of P. falciparum malaria worldwide with associated
uncertainty. This reflects the uncertainty in measures of risk that
results in a range of possible estimates globally from 349 to 553
million cases in 2007; similar to the range size in other malaria
burden estimations [1,3,5,7,84]. This elaborate modelling frame-
work has allowed the incorporation of uncertainty in our
knowledge of the intensity of transmission at any given location
with uncertainty in our knowledge of how this intensity influences
the rate of clinical episodes at that location, allowing the net
uncertainty to be propagated into final estimates of clinical
burden. Crucially, the joint simulation framework allows modelled
uncertainty to be aggregated across regions to provide our final
credible intervals for country and region-specific burden estimates,
a procedure that is not possible using the per-pixel prediction
approaches currently pervasive in disease mapping.
Figure 10. Pie chart of P. falciparum clinical cases in 2007. The pie chart shows the fraction of the 451 million cases of total clinical burden in
each of the World Health Organization regions (Protocol S2). In the pie the regions are ordered counterclockwise starting at the top, from highest to
lowest burden. The plotted area representing the EURO region is too thin to be visible. The thumbnail map shows the country composition of the
WHO regions for all 87 P. falciparum endemic countries.
doi:10.1371/journal.pmed.1000290.g010
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The WHO has recently used surveillance-based techniques to
estimate the combined burden of P. falciparum and P. vivax to be
247 million cases in 2006 (189–287) [8]. The WHO placed greater
reliance on data reported routinely through national health
management information systems (HMIS), which were subjected
to a range of evidence-based adjustments for nonattendance,
reporting rates, and diagnostic practices. These HMIS data were
used for national estimates in 77 of 107 countries considered
worldwide (Protocol S2). The fidelity of these estimates and their
sensitivity to assumptions underlying the suite of adjustment
factors was dependent on the quality and completeness of the
HMIS data from each country. In the 30 countries with the least
reliable national data, a predecessor of the prevalence-based
modelling protocol presented in this study was used [8,85]. The
results are shown for individual countries in Protocol S2. These
estimates were revised in 2009 but data have not been made
available for all countries [9].
Uncertainty in India
India is a country of considerable diversity in its current and
historic malaria ecology, a country which suffered in excess of a
million deaths PA during the colonial era [86]. Since its
independence in 1947, India has achieved remarkable malaria
control gains, reducing morbidity to 100,000 cases and mortality
to zero in 1965 [87] at the peak of the Global Malaria Eradication
Programme [53]. Since this time malaria resurgence has been
widely reported in the country [87–89]. The contemporary
burden is unknown [90–97] and is probably exacerbated by the
unique problem of urban malaria, maintained by Anopheles stephensi
[49,88,98].
India remains a massive source of uncertainty in our
cartography-based estimates (Results and Protocol S2), contribut-
ing over three-quarters (76%) of the uncertainty range in the
global incidence estimates. It is therefore important to explore
ancillary evidence for the plausibility of these cartographic
estimates of 102 (31–187) million compared to the much smaller
estimate derived from surveillance-based techniques: 10.65 (9.00–
12.41) million [8].
A wide range of factors can reduce the accuracy of surveillance
data. Low rates of care-seeking for malaria in the formal health
sector, unreliable diagnoses, poor record keeping, and inefficient
data transfer and collation systems can all combine to make the
number of cases formally reported a small fraction of the true
number of cases in a population. To mitigate these substantial
sources of bias in raw surveillance data, the approach taken by
WHO is to modify the raw data using a number of adjustment
parameters, which can include the proportion of people with fever
seeking formal-sector care, the reporting rate by facilities, and the
likely positivity rates amongst non-attending and non-slide–
confirmed cases of fever [8,85]. Such adjustments are essential,
but the validity of the final estimate is entirely dependent on the
values used for each parameter, which are drawn from a mixture
of health-system reported figures, secondary data of varying
fidelity, and ad-hoc decision rules. A key weakness of this approach
is that, in many cases, the true uncertainty around key parameter
values is not captured adequately.
In the case of India, raw surveillance data for 2006 reported 1.8
million malaria cases. Adjustments were made for care-seeking
behaviour and reporting rate by health facilities, which combined
to increase the estimate by a factor of 5.0–6.9, to the final figure of
10.65 (9.00–12.41) million [8], with the confidence range
primarily reflecting differing assumptions for positivity rate
amongst nonpresenting fevers. Assessing the validity of either the
individual adjustment parameters or the final estimate is difficult
since, by definition, gold-standard values for comparison do not
exist. However, numerous studies in India have compared case
numbers detected via routine surveillance with parallel commu-
nity-based longitudinal surveys and found disparities much larger
than the factor of approximately six used by the WHO. For
example, malaria incidence in the Kichha Primary Health Centre
(PHC) and Kharkhoda PHC were 23.5 and 38.9 times under-
reported, respectively [61]. Large discrepancies were also reported
in Gadarpur PHC (53.56) [62], Nichlaul PHC (20.36) [64] and
Ahmedabad City (96) [65]. For India, the WHO estimate makes
no allowance for misdiagnosis within the formal health sector,
although studies have shown that this can be substantial. In the
PHCs of ten districts in Uttar Pradesh, 75% of slide-confirmed
infections were missed when the slides were checked by a reference
centre [28], and an estimated 58% were missed in Bisra PHC
when fortnightly rather than weekly surveillance was used [63].
In completely independent work, the final estimate for malaria
mortality in India in 2006, taken from the ‘‘million deaths’’ verbal
autopsy study was approximately 200,000 deaths (Dhingra N, et
al., unpublished data). Assuming a conservative case fatality rate of
only one per 1,000 [99,100], this would lead to a morbidity
estimate much closer to those retrieved using cartographic
techniques—somewhere in the region of 200 million cases. Similar
arguments of plausible morbidity totals can be made using other
recent mortality estimates of 50,000 deaths in 1998 in 15 of 38
States and Union Territories [90,93]. In sum, we find that
cartography-based estimates are supported by, and resonate most
closely with, the findings in the recent literature [90–96], although
it should be acknowledged that there is likely to be a publication
bias in reports of problems over progress.
There is no perfect post-hoc correction to compensate for poor
malaria surveillance. Both methods using routine HMIS adjusted
for nonattendance, poor reporting, and inadequate diagnostics,
and those presented here, have limitations with respect to coverage
and quality of the input data for each model, and with respect to
underlying modelling assumptions. Both approaches to burden
estimation result in wide margins of confidence and the inevitable
plea from any such analysis is for accurate national reporting
systems or more empirical epidemiological data. It can be seen
clearly from these analyses that improvements in basic malario-
metric information in only four countries would radically reduce
uncertainty in the global estimates of the malaria burden.
Additionally, the approach presented does provide a standardized
method across all malaria-endemic countries, using a set of
transparent epidemiological rules allowing countries to be
compared without concerns about differences in national health
information quality or coverage.
A Hybrid Approach?
To allay some of the concerns about the use of cartographic
techniques in low-endemicity settings [101], we have also
investigated the possibility of combining the two burden estimation
processes for the 87 PfMECs.
Seven countries have ‘‘gold-standard’’ reporting systems
requiring no adjustment by either technique. These are in the
African Regional Office (AFRO): South Africa; in AMRO: Belize
and Panama; EMRO: Iran and Saudi Arabia; and EURO:
Kyrgyzstan and Tajikistan (7/87). In many PfMECs in the Africa+
region, an outdated cartographic technique was used by WHO
[8]. Since the new methods outlined here are an unambiguous
improvement, these were adopted for the following PfMECs: in
AFRO: Angola, Burkina Faso, Cameroon, Central African
Republic, Chad, Congo, Coˆte d’Ivoire, DRC, Equatorial Guinea,
The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Malawi,
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Mali, Mauritania, Mozambique, Niger, Nigeria, Sierra Leone,
Togo, Uganda, and Zimbabwe; and in EMRO: Yemen (25/87).
In addition, Mayotte in AFRO and French Guiana in AMRO
have no WHO estimates, so we default to the cartographic
approach (2/87). Conversely there are two small island nations in
AFRO (Cape Verde and the Comoros) for which we had no
contemporary PfPR data and the spatial resolution of mapping
was not ideal, so the WHO estimates were used (2/87).
We then calculated, for all countries, the ratio of the width of
the 95% credible interval to the point estimate obtained using the
cartographic method and ranked this relative uncertainty metric
by nation (Protocol S2). For those countries where this
cartography-based uncertainty ranked in the bottom half (i.e.,
the least uncertain, corresponding to a ratio of ,40), we adopted
our cartographic-based estimates. They were in AFRO: Benin,
Burundi, Ethiopia, Gabon, Kenya, Madagascar, Rwanda, Sene-
gal, United Republic of Tanzania, and Zambia; in EMRO:
Somalia and Sudan; in SEARO: India, Indonesia, and Myanmar;
and in WPRO: Papua New Guinea (16/87). Conversely, in
countries where cartography-based uncertainty was ranked in the
top half (ratio$40) we defaulted to the WHO estimate. They were
in AFRO: Botswana, Eritrea, Namibia, Sa˜o Tome´ and Prı´ncipe,
and Swaziland; in AMRO: Bolivia, Brazil, Colombia, Dominican
Republic, Ecuador, Guatemala, Guyana, Haiti, Honduras,
Nicaragua, Peru, Suriname, and Venezuela; in EMRO: Afghani-
stan, Djibouti, and Pakistan; in SEARO: Bangladesh, Bhutan,
Nepal, Sri Lanka, Thailand, and Timor-Leste; and in WPRO:
Cambodia, China, Lao People’s Democratic Republic, Malaysia,
Philippines, Solomon islands, Vanuatu, and Viet Nam (35/87).
This hybrid approach resulted in seven countries using gold
standard national reports, 43 nations using cartographic tech-
niques and 37 using the surveillance-based methods of WHO. The
percentage of the global burden estimated by each technique was
0.001%, 97.722%, and 2.277%, respectively. Using a hybrid
approach therefore makes very little difference to the global
clinical burden estimate for 2007, although it has a significant
impact on the absolute number of cases estimated for each country
(Protocol S2).
Interpreting Estimates
These estimates improve upon previous efforts, which used
epidemiological approaches to estimate the global burden of P.
falciparum clinical attacks in 2002 (515 million, interquartile range
300–660 million) [5], and more recent efforts to estimate
paediatric clinical events due to high parasite densities of P.
falciparum in Africa in 2000 (116 million, uncertainty interval 91–
258 million) [7]. The differences between these results and
previous efforts are not primarily due to differences in the base
year of analysis or definitions of a clinical attack, but stem largely
from differences in estimation of the endemicity-structured PARs.
In our previous global estimates [5], we adapted a historical,
categorical description of malaria endemicity, whilst in Africa we
[1,3,4] and others [6,7] have previously used a climate suitability
model of the likelihood of stable transmission as an index of
differences in transmission intensity [102,103]. The single largest
difference between previous work and the present iteration of P.
falciparum disease burden estimation is that neither previous
approach was based upon an empirically defined risk map of
malaria transmission [41]. Comparing estimates derived using
these different techniques, over various time periods, is not a sound
basis for investigating trends and should be avoided.
It is clear that investing in radically improved surveillance and/
or nationally representative malariometric surveys would substan-
tially increase the fidelity of national and, by extension, global
burden estimates. Because there are regional differences in the
uncertain relationship between transmission intensity and disease
outcome [42], more information derived from active case
detection studies would improve the precision in our estimates of
disease incidence within these transmission ranges. This informa-
tion, while welcome, is likely to make only small differences to the
computed risk in most scenarios of malaria transmission defined
here. As a consequence, we believe that until there is a universally
reliable reporting system for malaria cases worldwide to support
comprehensive surveillance-based estimates, a concerted effort to
map the changing spatial extents and intensity of transmission will
remain a valuable contribution to the future estimations of a
changing disease burden worldwide. In the short term, measuring
how the ‘‘denominator’’ changes with time is clearly easier and
cheaper than improving the global state of health information
systems.
Future Directions
Many improvements will be possible with further work. We
have not stratified incidence by age nor considered any of the
consequential morbid events, sequelae, or mortality. Systematic
biases in the identification of the extent of stable and unstable
transmission would clearly impact estimates, and developing the
datasets and techniques to address this problem is an important
avenue for future work. Nor have we modelled uncertainty in
HMIS reporting in unstable and low-stable transmission zones,
and this might be possible with a methodological hybrid
combining higher spatial resolution HMIS facility data with
geostatistical techniques [37]. Moreover, we have not been able to
consider some sources of uncertainty in the current framework; for
example, those concerning the enumeration of the underlying
population, based on collated census data; urban extent maps; and
UN population projections. Finally, we have not considered the
morbid burden posed by P. vivax. There are important differences
in the biology of P. vivax [104] which make its control [105], and
thus cartography-based burden estimation, problematic: its
tendency to cause relapses [106], the routine reliability of parasite
diagnosis when coincidentally prevalent with P. falciparum
[107,108] and the less well-defined relationship between trans-
mission intensity and disease outcome. These all make an
informed cartography of P. vivax distribution and estimations of
disease burden considerably more complex than for P. falciparum.
We do not underestimate the likely disease burden of P. vivax
malaria [109–112], but new, innovative approaches based on an
understanding of the clinical epidemiology and better cartography
are required to improve upon current efforts to define the burden
due to P. vivax.
It is worth reiterating that if the international community wishes
to demonstrate progress in malaria control, then the quantity and
timeliness of prevalence information and parasite-specific surveil-
lance records must dramatically improve. This is true for all
countries but is particularly important in India, Nigeria, DRC,
and Myanmar because of the large populations at risk and the
paucity of existing malariometric information. These improve-
ments in information collection and provision are as important
across space (to be geographically representative of all transmission
settings and intervention scenarios) as they are through time, so
that impact can be evaluated in a timely manner. Conceptually,
we also envisage that significant progress will be made in
improving the accuracy of these estimates by hybridising
cartographic and surveillance-based approaches. This would be
best achieved by combining geopositioned HMIS facility data with
geostatistical model outputs [37], so that the relative uncertainty of
each can be compared and complementary information from both
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sources combined in a single coherent spatial framework. Globally,
this is likely to be of particular utility in those areas of low and
unstable transmission where surveillance capabilities are often
more robust and correspondingly where prevalence data are often
rare as the number of people needed to be sampled to find
infections is prohibitive [12].
The malaria clinical burden estimates presented in this paper
are driven by the underlying model of global prevalence [41]. This
global malaria map is, to our knowledge, the first evidence-based
attempt to define populations at risk of different levels of parasite
transmission. It is needed in order to define the ranges of disease
outcomes at a global scale and can serve as the benchmark for
malaria disease burden estimations. The map will inevitably
change with time as new information on the spatial extents of
transmission and new PfPR2–10 data become increasingly available
with the scale-up of interventions. The time–space functionality of
the geostatistical model will increasingly capture the effects of
scaled intervention efforts to reduce transmission, causing the size
of the PfPR used to compute disease burden to change. Revising
the limits and endemicity maps from this baseline and propagating
these changes through to revised enumerations of clinical burden
thus represents a useful complementary technique to assessing the
impact of financing [113] on our progress towards international
development targets for reducing malaria burden [59,114].
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Editors’ Summary
Background. Malaria is a major global public-health
problem. Nearly half the world’s population is at risk of
malaria, and Plasmodium falciparum malaria—the deadliest
form of the disease—causes about one million deaths each
year. Malaria is a parasitic disease that is transmitted to
people through the bite of an infected mosquito. These
insects inject a parasitic form known as sporozoites into
people, where they replicate briefly inside liver cells. The liver
cells then release merozoites (another parasitic form), which
invade red blood cells. Here, the merozoites replicate rapidly
before bursting out and infecting more red blood cells. This
increase in the parasitic burden causes malaria’s
characteristic symptoms—debilitating and recurring fevers
and chills. Infected red blood cells also release gametocytes,
which infect mosquitoes when they take a blood meal. In the
mosquito, the gametocytes multiply and develop into
sporozoites, thus completing the parasite’s life cycle.
Malaria can be prevented by controlling the mosquitoes
that spread the parasite and by avoiding mosquito bites.
Effective treatment with antimalarial drugs also helps to
reduce malaria transmission.
Why Was This Study Done? In 1998, the World Health
Organization (WHO) and several other international agencies
launched Roll Back Malaria, a global partnership that aims to
provide a coordinated, global approach to fighting malaria.
For this or any other malaria control initiative to be effective,
however, an accurate picture of the global clinical burden of
malaria (how many people become ill because of malaria
and where they live) is needed so that resources can be
concentrated where they will have the most impact.
Estimates of the global burden of many infectious diseases
are obtained using data collected by national surveillance
systems. Unfortunately, this approach does not work very
well for malaria because in places where malaria is endemic
(always present), diagnosis is often inaccurate and national
reporting is incomplete. In this study, therefore, the
researchers use an alternative, ‘‘cartographic’’ method for
estimating the global clinical burden of P. falciparum malaria.
What Did the Researchers Do and Find? The researchers
identified seven P. falciparum malaria-endemic countries that
had sufficiently reliable health information systems to
determine the national clinical malaria burden in 2007
directly. They divided the other 80 malaria endemic countries
into countries with a low risk of transmission (unstable
transmission) and countries with a moderate or high risk of
transmission (stable transmission). In countries with unstable
transmission, the researchers assumed a uniform annual
clinical incidence rate of 0.1 cases per 1,000 people and
multiplied this by population sizes to get disease burden
estimates. In countries with stable transmission, they used a
modeled relationship between clinical incidence (number of
new cases in a population per year) and prevalence (the
proportion of a population infected with malaria parasites)
and a global malaria endemicity map (a map that indicates
the risk of malaria infection in different countries) to estimate
malaria incidences. Finally, they used a technique called
‘‘joint simulation’’ to quantify the uncertainty in these
estimates. Together, these disease burden estimates gave
an estimated global burden of 451 million clinical cases of P.
falciparum in 2007. Most of these cases occurred in areas of
stable transmission and more than half occurred in India,
Nigeria, the Democratic Republic of the Congo, and
Myanmar. Importantly, these four nations alone
contributed nearly half of the uncertainty in the global
incidence estimates.
What Do These Findings Mean? These findings are
extremely valuable because they provide a global map of
malaria cases that should facilitate the implementation and
evaluation of malaria control programs. However, the
estimate of the global clinical burden of P. falciparum
malaria reported here is higher than the WHO estimate of
247 million cases each year that was obtained using
surveillance-based methods. The discrepancy between the
estimates obtained using the cartographic and the
surveillance-based approach is particularly marked for
India. The researchers discuss possible reasons for these
discrepancies and suggest improvements that could be
made to both methods to increase the validity and precision
of estimates. Finally, they note that improvements in the
national prevalence surveys in India, Nigeria, the Democratic
Republic of the Congo, and Myanmar would greatly reduce
the uncertainty associated with their estimate of the global
clinical burden of malaria, an observation that should
encourage efforts to improve malaria surveillance in these
countries.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000261.
N A PLoS Medicine Health in Action article by Hay and
colleagues, a Research Article by Guerra and colleagues,
and a Research Article by Hay and colleagues provide
further details about the global mapping of malaria risk
N Additional national and regional level maps and more
information on the global mapping of malaria are available
at the Malaria Atlas Project
N Information is available from the World Health Organiza-
tion on malaria (in several languages)
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish)
N Information is available from the Roll Back Malaria
Partnership on its approach to the global control of
malaria (in English and French)
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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